Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

[slayer74]

Koncern Johnson & Johnson wiedział od dekad o obecności azbestu w produkowanym przez niego pudrze dla niemowląt - donosi agencja Reutera. Akcje koncernu spadły w piątek o niemal 11 proc.
https://www.rp.pl/Biznes/181219580-John ... 1hxFlp69Y0

[slayer74]

Johnson & Johnson Tops Q4 Earnings Estimate, Sees 2019 Sales Near $81 Billion
https://www.thestreet.com/investing/ear ... n-14840666
---
Johnson & Johnson (NYSE: JNJ) released its fourth-quarter financial results before the markets opened on Tuesday. The health care giant said that it had in $1.97 earnings per share (EPS) and $20.39 billion in revenue, which compares with consensus estimates of $1.95 in EPS on revenue of $20.17 billion. In the same period of last year, the company said it had EPS of $1.74 and $20.2 billion in revenue.

During the quarter, operational sales results increased 3.3% and the negative impact of currency was 2.3%. Domestic sales increased 1.5% and International sales increased 0.4%, reflecting operational growth of 5.1% and a negative currency impact of 4.7%.

In terms of its sales, Johnson & Johnson reported as follows:

Prescription Drug sales increased 5.3% year over year to $10.19 billion.
Health Business sales were flat at $3.54 billion.
Medical Devices and Diagnostics Business sales dropped 4.4% to $6.67 billion.
Looking ahead to the 2019 full year, the company expects to see EPS in the range of $8.50 to $8.65 and sales between $80.4 billion and $81.2 billion. The consensus estimates are $8.61 in EPS and $82.68 billion in revenue.
https://247wallst.com/healthcare-busine ... od-enough/

[slayer74]

Sprawa sądowa najważniejsza dla Johnson & Johnson
https://pl.investing.com/analysis/spraw ... -200224677

[slayer74]

Johnson & Johnson Edges Higher After FDA Approves Nasal Spray Antidepressant
Johnson & Johnson shares were rising Wednesday after the U.S. Food & Drug Administration approved a controversial antidespressant treatment, the first in three decades, even as it cautioned against potential misuse.

https://www.thestreet.com/investing/sto ... t-14888232

[slayer74]

Johnson & Johnson (J&J) wypłaci kobiecie, u której w 2017 r. zdiagnozowano raka (międzybłoniaka), 29 mln USD odszkodowania — orzekł sąd najwyższy w Oakland (Kalifornia, USA), poinformował „The Guardian”.

https://www.pb.pl/j-j-przegral-proces-955872

[slayer74]

Johnson & Johnson Still Has Multiple Growth Drivers to Power Its Stock
https://www.thestreet.com/investing/sto ... s-14948711

[slayer74]

Johnson & Johnson: Follow Warren Buffett's Advice and Be Greedy
https://www.thestreet.com/investing/sto ... y-14977398

[slayer74]

Purdue Pharma, producent opioidowych leków kontrolowany przez rodzinę Sackler, miał zaoferować 10-12 mld USD aby zawrzeć ugodę i zamknąć sprawę tysięcy pozwów.

Firma znana z produkcji leku przeciwbólowego OxyContin poinformowała BBC, że szuka możliwości „globalnego rozwiązania” sprawy pozwów. NBC, które jako pierwsze poinformowało o gotowości Purdue do zawarcia ugody, podało, że zawierałaby ona także wycofanie się rodziny Sackler ze spółki.

Purdue jest jednym z 22 producentów, dystrybutorów i sprzedawców leków opioidowych, których wskazano w ponad 2 tys. pozwów mających trafić do sądu w październiku. Pozwy skierowały amerykańskie stany, miasta i hrabstwa. Zarzucają w nich firmom stosowanie oszukańczych praktyk przy sprzedaży opioidów, które doprowadziły do kryzysu uzależnień w USA. Każdego dnia średnio 130 Amerykanów umiera z powodu przedawkowania opioidów, wynika z danych Amerykańskiego Centrum Zapobiegania i Kontroli Chorób.

W poniedziałek Johnson & Johnson został skazany w USA na zapłatę 572 mln USD za przyczynienie się do uzależnienia od opioidów w stanie Oklahoma.

https://www.pb.pl/amerykanski-producent ... ody-968892

[slayer74]

Gigantyczna grzywna dla Johnson & Johnson w związku z 'kryzysem opioidowym'. Czy branża farmaceutyczna ma problem?
https://www.paszport.ws//gigantyczna-gr ... utyczna-ma

[slayer74]

Summary
JNJ has a moderate long-term outlook that is strengthened by its robust business segments and strong management team.

The company's large scale and broad scope pose anti-competitive, regulatory, and legal challenges.

The scale of JNJ’s consumer, pharmaceutical, and medical devices segments as well as JNJ’s commitment to robust R&D and acquisition spending provide a strong competitive advantage.
https://seekingalpha.com/article/429430 ... ngcom_feed

[slayer74]

Janssen, spółka z grupy Johnson & Johnson, została skazana przez sąd w USA na zapłacenie 8 mld USD odszkodowania za szkody spowodowane przez jeden z jej leków.

To rekordowa w tym roku kwota odszkodowania. Janssen został skazany za niewłaściwy marketing leku Risperdal, który jak się okazało, powodował rośnięcie piersi u dorastających chłopców. Oskarżycielem w procesie jest Nicholas Murray, mieszkaniec stanu Maryland, który zaczął przyjmować lek w terapii autyzmu.
Eksperci uważają, że wydany werdykt nie utrzyma się w procesie apelacyjnym. Pomimo to będzie znaczącym sygnałem ostrzegawczym dla Johnson & Johnson, bo koncern stoi w obliczu ponad 13 tys. pozwów dotyczących Risperdalu. Ponad 7 tys. trafiło do sądu w Filadelfii.

https://www.pb.pl/spolka-zalezna-johnso ... nia-972526

[slayer74]

Johnson & Johnson: Dividend King With A Secure Payout

https://www.investing.com/analysis/john ... -200521765

[slayer74]

Dywidendy:
The Best Dividend Stock to Own Now
Filmik autora strony https://www.mrfreeat33.com/
Akcje JNJ stanowią znaczną część jego portfela.

https://www.youtube.com/watch?v=TY74KKpjiIQ

[slayer74]

Dywidendy
JNJ increases in its dividend, upping the quarterly dividend 6.32% from $0.95 to $1.01 DY 2.69%

[slayer74]

Johnson & Johnson to stop selling talc baby powder in U.S. and Canada

(Reuters) - Johnson & Johnson on Tuesday announced it would stop selling its talc Baby Powder in the United States and Canada, saying demand had dropped in the wake of what it called "misinformation" about the product’s safety amid a barrage of legal challenges.

J&J faces more than 19,000 lawsuits from consumers and their survivors claiming its talc products caused cancer due to contamination with asbestos, a known carcinogen. Many are pending before a U.S. district judge in New Jersey.

"I wish my mother could be here to see this day," said Crystal Deckard, whose mother Darlene Coker alleged Baby Powder caused her mesothelioma. She dropped the suit filed in 1999 after losing her fight to compel J&J to divulge internal records. Coker died of mesothelioma in 2009.

In its statement, J&J said it "remains steadfastly confident in the safety of talc-based Johnson's Baby Powder," citing "decades of scientific studies."

J&J has faced intense scrutiny of the safety of its baby powder following an investigative report by Reuters in 2018 that found the company knew for decades that asbestos lurked in its talc.

Internal company records, trial testimony and other evidence show that from at least 1971 to the early 2000s, the company's raw talc and finished powders sometimes tested positive for small amounts of asbestos.

(To read the Reuters special report click, https://www.reuters.com/investigates/sp ... on-cancer/ )

The Reuters article prompted a stock selloff that erased about $40 billion from J&J’s market value in one day and created a public relations crisis as the blue-chip healthcare conglomerate faced widespread questions about the possible health effects of one of its most iconic products.

J&J has also been the target of a federal criminal investigation into how forthright it has been about its talc products’ safety, an investigation by 41 states into its baby powder sales, which it disclosed in April, and an investigation into health risks of asbestos in talc-containing consumer products by a Congressional subcommittee.

U.S. Representative Raja Krishnamoorthi, who led the Congressional inquiry, described J&J's decision to stop selling talc baby powder as "a major victory for public health", adding: "My Subcommittee’s 14-month investigation revealed that Johnson & Johnson knew for decades that its product contains asbestos."

In response to evidence of asbestos contamination presented in media reports, in the court room and on Capitol Hill, J&J has repeatedly said its talc products are safe, and do not cause cancer.

Apart from the baby powder controversy, the company revered by millions of consumers and one of the most trusted brands in America, more recently has faced a series of legal and reputational challenges.

J&J has said it has been named as a defendant, along with other drugmakers, in more than 2,900 lawsuits alleging the companies improperly promoted addictive opioids.

In August, an Oklahoma judge rendered the first verdict in that litigation, ordering J&J to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers.

J&J is appealing the Oklahoma judge's ruling and has denied it caused the opioid crisis.

Johnson & Johnson on Tuesday said it had stopped shipping talc baby powder when the COVID-19 crisis led to limits on shopping and manufacturing, and that now it would wind down North American sales.

"Demand for talc-based Johnson’s Baby Powder in North America has been declining due in large part to changes in consumer habits and fueled by misinformation around the safety of the product and a constant barrage of litigation advertising," it said in a statement.

Sold continuously since 1894, Johnson’s Baby Powder now accounts for only about 0.5% of its U.S. consumer health business, the company said. But it remains a symbol of the company's family-friendly image.

An internal J&J marketing presentation from 1999 refers to the baby products division, with Baby Powder at the core, as J&J’s “#1 Asset,” grounded in “deep, personal trust" and a 2003 internal memo described it as a "sacred cow," Reuters reported.

Christie Nordhielm, a professor of marketing at Georgetown, said it appears J&J made its decision to withdraw from the market while consumers are preoccupied with the pandemic. "It's a nice time to quietly do it," she said, adding "it will minimize the reputational hit."

Shares of J&J were unchanged in after-hours trading following the disclosure.

"We will continue to vigorously defend the product, its safety, and the unfounded allegations against it and the Company in the courtroom," Johnson & Johnson said. "All verdicts against the company that have been through the appeals process have been overturned."

Krystal Kim, one of 22 women with ovarian cancer whose case in St. Louis resulted in a 2018 jury verdict of $4.69 billion against J&J, said the decision was "a step in the right direction." J&J has appealed that verdict.

Nevertheless, J&J's legal challenges likely will continue, some lawyers said. In April, a New Jersey judge ruled that thousands of plaintiffs who allege J&J's talc products caused cancer can go forward with their claims, but face limits on what expert testimony would be allowed in trials.

"Just taking it off the shelf today doesn’t end the litigation by a long shot," said Loyola Law Professor Adam Zimmerman.

Asbestos is known to cause cancer that emerges decades after exposure. Cases involving asbestos-containing products removed from the marketplace long ago "continue to be litigated very actively to this day," Zimmerman said.

Many of the lawsuits allege Baby Powder caused plaintiffs' mesothelioma, an incurable cancer of the lining of the lungs and other organs commonly caused by asbestos.

"Just as J&J vows to continue fighting vigorously in the courts, we look forward to meeting them there as we continue to pursue justice for our clients," said Chris Placitella, one of the lead lawyers representing plaintiffs in the cases consolidated in a New Jersey federal court.

J&J said it will continue to sell cornstarch-based baby powder in North America, and will sell both its talc and cornstarch-based products in other markets around the world.

https://www.investing.com/news/economy/ ... da-2177400